Does ADALIMUMAB Cause Malignant neoplasm progression? 161 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 161 reports of Malignant neoplasm progression have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.
161
Reports of Malignant neoplasm progression with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
15
Deaths
13
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ADALIMUMAB?
Of the 161 reports, 15 (9.3%) resulted in death, 13 (8.1%) required hospitalization, and 7 (4.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 161 reports have been filed with the FAERS database.
What Other Side Effects Does ADALIMUMAB Cause?
Drug ineffective (71,926)
Pain (37,514)
Arthralgia (35,592)
Rheumatoid arthritis (29,817)
Fatigue (29,420)
Injection site pain (28,679)
Headache (19,891)
Nausea (19,299)
Rash (18,690)
Pain in extremity (18,319)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ADALIMUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
ADALIMUMAB vs ADALIMUMAB-AACF
ADALIMUMAB vs ADALIMUMAB-AATY
ADALIMUMAB vs ADALIMUMAB-ADAZ
ADALIMUMAB vs ADALIMUMAB-ADBM
ADALIMUMAB vs ADALIMUMAB-AFZB